price close busi april
biomed devic servic
record new patient add investor look past
bottom line despit impact late post
anoth except quarter revenu overal well cg/
street consensu estim manag note record new patient addit
impress ou growth withdrew guidanc due uncertainti regard
impact new/exist patient manag also mention
start see rebound late april suggest impact
may somewhat lighter anticip physicians/pati quickli
transit telemedicin furthermor manag note new
patient self-train use patient educ materi import statist
era social distanc also demonstr ease-of-us
system despit potenti impact covid new patient add near-
term see reason chang view market remain earli
stage penetr across variou use case within diabet
manufactur focu product pipelin profession use hospit
gestat posit compani strong line-up fulli equip lower cost
technolog sum remain bullish near- long-term product pipelin
grow opportun deliv signific upsid despit
result deliv revenu cg/consensu
expect us sale grew y/i vs cg estim
ou revenu equal impress y/i vs
estim gross margin y/i
oper margin significantli demonstr
leverag model despit continu invest sg
covid impact rel unaffect covid withdraw
full year guidanc note uncertainti new patient add next two
month addit pivot trial delay six month given clinic closur
manag express uncertainti site would back
run patient would still will go remind
origin track approv limit launch broader launch
plan earli
futur growth opportun ou hospital-us telemedicin beyond
highlight sever futur initi support growth beyond
first ww cgm penetr remain earli inning compani work
secur access new market includ japan manag note
signific runway remain across board call second covid may
serv acceler hospital-us opportun given import remot
monitor glucos hospit set higher-risk covid mortal
diabet inpati materi impact revenu quarter
expect limit revenu highlight effort compani
unlock hospit opportun near-term covid patient longer-
term goal captur clinic data util experi
acceler broader approval/clear fda lastli note rapid growth
endocrinologist use telemedicin potenti signific tailwind
cgm adopt given import remot data tracking/log virtual
manag diabet someth well-suit point
recent held webinar regard telemedicin endo note
physician attend demonstr newfound interest physician side
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
capac constraint invest growth clear sever quarter
effort lower barrier adopt shift patient pharmaci channel
materi acceler growth patient demand system
patient clinician across patient popul said growth
came larg backdrop suppli constraint dynam eas
compani doubl capac look
despit covid compani note suffici suppli level meet current
demand plan increas dtc advertis clariti
rest year importantli leverag aforement infrastructur
invest support launch said invest come
expens near-term headwind gm compani also plan build
third manufactur facil asia add capac sit closer key ou
opportun come focu manag repeatedli spoke
opportun see within popul within insulin
intens popul believ approach total patient
much larger non-insulin-intens notabl receiv promis
earli clinic data non-intens popul includ cost-benefit analysi
intermountain healthcar show use cgm save thousand
dollar per patient per year partner digit health manag
compani like welldoc livongo unlock valu long-term said
non-intens opportun reli lower-cost sensor posit
growth driver possibl later pivot trial delay continu what
reimburs pathway remain nascent non-intens
expect need addit clinic data refin util model
guidanc chang estim
withdrew revenu guidanc due uncertainti relat
remind revenu origin guid februari
growth made follow chang estim
figur summari estim revis
high-growth medic devic comp group current trade
ev/sal appli premium given diabet industri insul
biomed devic servic
except ep newold newold newold revenu net
cgm particular impact rel sub-industri within
med-tech sum maintain price target price target base
ev/sal multipl appli sale estim
assum cash debt share outstand
figur matrix discount rate impli share price target
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
canaccord genuiti estim compani report compani report
biomed devic servic
